Falkowski Krzysztof, Bączkowicz Dawid
Department of Orthopaedics and Traumatology of the Musculoskeletal System, Institute of Medical Sciences, University of Opole, 45-758 Opole, Poland.
Department of Physiotherapy, Faculty of Physical Education and Physiotherapy, Opole University of Technology, 45-758 Opole, Poland.
J Clin Med. 2025 May 19;14(10):3557. doi: 10.3390/jcm14103557.
: Intra-articularly administered hyaluronic acid (HA) products improve the mechanical properties of the synovial fluid (SF) in an osteoarthritic (OA) joint and thus improve joint motion quality. However, current diagnostic methods, used to assess the clinical effectiveness of HA-based therapy are based on subjective tools, and are unable to deliver solid data about the actual impact of this molecule on joint functioning. Consequently, the aim of this study was to objectively assess the effect of HA IA injection on joint motion quality with vibroarthrography (VAG) and the subsequent evaluation of patient clinical status. : A total of 40 patients with knee OA and 50 healthy individuals as the control group were enrolled in this non-randomized clinical and were subjected to therapy consisting of a single IA administration of highly concentrated HA gel (Biolevox™ HA ONE). The therapy assessment included an evaluation of joint motion quality with the VAG method and a subsequent evaluation of the knee joint function using the WOMAC questionnaire for up to 60 days after the therapy. : A single IA injection of HA led to an immediate and sustained improvement of the motion quality of OA-affected synovial joints, as proven by the significant reduction in all measured vibroacoustic emissions (VMS, R4, P1, and P2). Furthermore, this was followed by a significant improvement in all WOMAC sub-scales, observed at 30 and 60 days after the therapy. : The results of this study demonstrate that an IA-HA injection can improve the motion quality of OA-affected joints. Importantly, the observed improvement in joint motion quality is directly correlated with early recovery of joint function. These findings provide objective evidence that HA effectively enhances OA-affected joint biomechanics, contributing to a better understanding of the actual impact of this prevalent OA therapy on knee joint motion quality.
关节腔内注射透明质酸（HA）产品可改善骨关节炎（OA）关节滑液（SF）的力学性能，从而提高关节运动质量。然而，目前用于评估基于HA治疗的临床有效性的诊断方法基于主观工具，无法提供关于该分子对关节功能实际影响的确切数据。因此，本研究的目的是通过振动关节造影（VAG）客观评估HA关节内注射对关节运动质量的影响，并随后评估患者的临床状态。
共有40例膝骨关节炎患者和50名健康个体作为对照组纳入这项非随机临床试验，并接受单次关节内注射高浓度HA凝胶（Biolevox™ HA ONE）的治疗。治疗评估包括使用VAG方法评估关节运动质量，以及在治疗后长达60天使用WOMAC问卷对膝关节功能进行后续评估。
单次关节内注射HA可立即并持续改善受OA影响的滑膜关节的运动质量，所有测量的振动声发射（VMS、R4、P1和P2）显著降低证明了这一点。此外，治疗后30天和60天观察到所有WOMAC子量表均有显著改善。
本研究结果表明，关节内注射HA可改善受OA影响关节的运动质量。重要的是，观察到的关节运动质量改善与关节功能的早期恢复直接相关。这些发现提供了客观证据，证明HA有效地增强了受OA影响关节的生物力学，有助于更好地理解这种常见的OA治疗方法对膝关节运动质量的实际影响。
